Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atrial Fibrillation Recurrent Clear all
Not listed Phase 2 Interventional

Comparison of Redo PVI With vs. Without Renal Denervation for Recurrent AF After Initial PVI

NCT01959997
View directory record Official record
Conditions
Atrial Fibrillation, Arterial Hypertension
Interventions
Redo PVI, PVI + RDN
Procedure
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation
Network
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Oct 21, 2026, 9:58 PM EDT
Not listed Not applicable Interventional

Pulmonary Vein Antrum Isolation (PVAI) Plus Scar Homogenization and Non-PV Triggers Ensure Long-term Recurrence-free Survival in Non-paroxysmal Atrial Fibrillation

NCT01672138
View directory record Official record
Conditions
Persistent Atrial Fibrillation, Long-standing Persistent Atrial Fibrillation
Interventions
Pulmonary Vein Antrum Isolation, scar homogenization, Non-PV triggers ablation
Procedure
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 21, 2026, 9:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

CARTO® 3 System and Real Time Intracardiac Ultrasound

NCT01716663
View directory record Official record
Conditions
Atrial Fibrillation, Paroxysmal AF
Interventions
Catheter Ablation
Device
Lead sponsor
Biosense Webster, Inc.
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
26
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Santa Barbara, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Oct 21, 2026, 9:58 PM EDT
Active, not recruiting Not applicable Interventional

Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

NCT06735534
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
FARAPULSE™ Pulsed Field Ablation System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
33
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 21, 2026, 9:58 PM EDT
Not listed No phase listed Observational

Implanted Loop Recorder Post Atrial Fibrillation Ablation

NCT00915720
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Thoracic & Cardiovascular Healthcare Foundation
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Phase 4 Interventional Results available

Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation

NCT00552084
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Fish oil, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Not applicable Interventional Results available

TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation

NCT03354663
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
TactiCath SE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
Little Rock, Arkansas • La Jolla, California • Redwood City, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Not applicable Interventional

Recurrent Atrial Fibrillation

NCT02898545
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
SEEQ monitor
Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation

NCT00402363
View directory record Official record
Conditions
Fibrillation, Atrial
Interventions
omega-3-acid ethyl esters, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
178
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 149 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 21, 2026, 9:58 PM EDT
Terminated No phase listed Observational

Left Atrial Appendage Closure With WATCHMAN FLX Device in Recurrent Gastrointestinal Bleeding: The GI-FLX Registry

NCT06052358
View directory record Official record
Conditions
Atrial Fibrillation, GI Bleeding
Interventions
LAAC with Watchman FLX device
Device
Lead sponsor
Kansas City Heart Rhythm Research Foundation
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Overland Park, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Phase 2 Interventional Results available

2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter-based Ablation

NCT04433091
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
2-Hydroxybenzylamine, Placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
22 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Not applicable Interventional

POLARx Post Approval Study (POLARx PAS)

NCT06170606
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
Boston Scientific Cardiac Cryoablation System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 21, 2026, 9:58 PM EDT
Not listed Not applicable Interventional

Natural History of COVID-19-Related Atrial Fibrillation

NCT04830774
View directory record Official record
Conditions
COVID-19, Atrial Fibrillation New Onset
Interventions
ILR, PMK, ICD
Device
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Kansas City, Kansas • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 21, 2026, 9:58 PM EDT
Active, not recruiting No phase listed Observational

P-wave Duration and Local Potential as Predictors of AF Recurrence Following Pulmonary Vein Isolation

NCT07471308
View directory record Official record
Conditions
Atrial Fibrillation (AF), Atrial Fibrillation Patients Treated With the FARAPULSE™ PFA System, Atrial Fibrillation (Paroxysmal), Pulmonary Vein Isolation
Interventions
AF Recurrence RIsk Assessment post pulmonary vein isolation
Device
Lead sponsor
CathVision ApS
Industry
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Phase 3 Interventional

Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation

NCT01173809
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Amiodarone
Drug
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Not applicable Interventional

Cardiac Rehab Post-atrial Fib Ablation

NCT05450731
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
12-week supervised exercise based cardiac rehabilitation program
Other
Lead sponsor
MultiCare Health System Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 21, 2026, 9:58 PM EDT
Completed No phase listed Observational

Redo AF Sub Study (of the Pure EP 2.0 Main Study)

NCT04964440
View directory record Official record
Conditions
Atrial Fibrillation Recurrent
Interventions
Pure-EP
Device
Lead sponsor
BioSig Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Not applicable Interventional

Cryoballoon vs. Rhythmia Guided Ablation for Recurrent AFib

NCT03811795
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
ECG monitoring with a Kardia Mobile monitor
Other
Lead sponsor
Valley Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
West Des Moines, Iowa • Paramus, New Jersey • Springfield, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 21, 2026, 9:58 PM EDT
Not listed Phase 3 Interventional

Use of Colchicine to Decrease Atrial Fibrillation Recurrence After Ablation

NCT05459974
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Colchicine 0.6 mg, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Oct 21, 2026, 9:58 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence

NCT04704050
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Fibrillation Recurrent
Interventions
dronedarone 400 mg Oral Tablet, Placebo
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Colorado Springs, Colorado • Atlanta, Georgia • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 21, 2026, 9:58 PM EDT
Terminated Phase 4 Interventional

The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)

NCT00343499
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
valsartan
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
Ogden, Utah • Salt Lake City, Utah • St. George, Utah
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 21, 2026, 9:58 PM EDT
Completed Not applicable Interventional Results available

Mapping Electrogram Morphology Recurrence for Atrial Fibrillation Ablation

NCT03082963
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Electrogram Morphology Mapping (EMR)
Device
Lead sponsor
Jeffrey Goldberger
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 21, 2026, 9:58 PM EDT
Terminated Phase 1 Interventional

Evaluate Use of Mangosteen Juice Added to Usual Care in Reducing Risk of Recurrent Atrial Fibrillation

NCT00951301
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
mangosteen juice, placebo juice
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 21, 2026, 9:58 PM EDT
Terminated Phase 3 Interventional Results available

Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion

NCT01349491
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Ranolazine, Matching placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 21, 2026, 9:58 PM EDT